TenNor Therapeutics gets FDA orphan drug status for TNP-2092 in prosthetic joint infections

TenNor Therapeutics has secured orphan drug designation from the US Food and Drug Administration (FDA) for its multitargeting drug conjugate TNP-2092 for the treatment of prosthetic joint infections. According to the Chinese biopharma company, biofilm infections associated with prosthetic joints, central venous catheters, artificial heart valves, and More...

by pharmanewsdaily | Published 1 day ago
By pharmanewsdaily On Sunday, January 19th, 2020
0 Comments

BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome

BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients having relapsed/refractory acute myeloid leukemia (AML), More...

By pharmanewsdaily On Sunday, January 19th, 2020
0 Comments

Frazier Healthcare Partners raises $617m for life sciences fund

Frazier Healthcare Partners has closed its third life sciences fund – Frazier Life Sciences X, at more than $617 million in capital commitments. The Seattle-based private equity and venture capital firm More...

By pharmanewsdaily On Sunday, January 19th, 2020
0 Comments

Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic More...

By pharmanewsdaily On Saturday, January 18th, 2020
0 Comments

Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the More...

By Soujanya Ravi On Thursday, January 16th, 2020
0 Comments

Element Biosciences raises $80m for genomic sequencing solutions

Californian biotechnology startup Element Biosciences, which focuses on developing genomic sequencing solutions for research and diagnostic markets, has raised $80.3 million in a Series B financing round. The financing More...

By pharmanewsdaily On Wednesday, January 15th, 2020
0 Comments

Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon

Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease patients, as per the latest More...

By pharmanewsdaily On Wednesday, January 15th, 2020
0 Comments

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral sclerosis (ALS). The late-stage More...

By pharmanewsdaily On Monday, January 13th, 2020
0 Comments

Lilly to acquire US dermatology drug company Dermira for $1.1bn

Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma More...

By pharmanewsdaily On Monday, January 13th, 2020
0 Comments

NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company

NeuroBo Pharmaceuticals,  a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing More...